|
|
|
| Effect of Sevelamer Carbonate on Microinflammation and Prognosis in Patients with Chronic Renal Failure Complicated with Hyperphosphatemia |
| HE Dan, LU Zhifeng, LU Jingjuan |
| Changshu Second People’s Hospital, Jiangsu Changshu 215500, China |
|
|
|
|
Abstract Objective: To investigate the effect of Sevelamer carbonate on microinflammation and prognosis in patients with chronic renal failure complicated with hyperphosphatemia, and to explore its microinflammation status and treatment measures. Methods: 80 patients with chronic renal failure complicated with hyperphosphorus were selected from August 2017 to August 2018 in our hospital. The patients were divided into observation group (40 cases) and control group (40 cases), according to the simple random grouping method. The control group was treated with calcium carbonate on the basis of routine hemodialysis, while the control group was treated with calcium carbonate on the basis of routine hemodialysis. Four weeks after treatment, the levels of TNF-alpha, CRP, IL-6, blood phosphorus, calcium and parathyroid hormone (iPTH) and the incidence of adverse reactions were compared between the two groups before and after treatment. Results: After treatment, the levels of TNF-a, CRP and IL-6 in the two groups were significantly lower than those before treatment, and the levels of each index in the observation group were significantly lower than those in the control group (P < 0.05); the levels of blood phosphorus, iPTH, calcium-phosphorus product in the two groups were significantly lower (P < 0.05), and the levels of each index in the observation group were significantly lower than those in the control group (P < 0.05). The difference was statistically significant (P < 0.05); the levels of serum calcium and bicarbonate in the two groups were significantly higher than those in the control group, and the level of bicarbonate in the control group was significantly lower than that in the observation group (P < 0.05); there was no statistical difference in the incidence of adverse events between the two groups (P < 0.05). Conclusion: Sevelamer carbonate can effectively reduce the level of inflammatory factors and regulate the level of blood phosphorus and calcium in patients with chronic renal failure combined with hyperphosphatemia, with good safety.
|
|
|
|
|
|
[1] 魏青,汤日宁,刘必成.慢性肾功能不全患者高磷血症的治疗进展[J].东南大学学报(医学版),2014,33(4):536~540.
[2] 姜鸿,庄晶,张长荣,等.司维拉姆对规律血液透析高磷血症患者血清炎症因子水平的影响[J].现代生物医学进展,2016,16(35):6919~6922.
[3] 中国中西医结合学会肾脏疾病专业委员会.慢性肾衰竭中西医结合诊疗指南[J].河北中医,2016,38(2):313~317.
[4] Arora A,Anand AC,Kumar A,et al.INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy,Biologicals,Immunosupressants,or Corticosteroids.[J].Clin Exp Hepatol,2018,8(4):403~431.
[5] Porter IE 2nd,Palmer WC,Parker AS,et al.Prevalence of nephrolithiasis in patients with chronic liver disease:a case-control study[J]. Clin Exp Hepatol,2018,8(4):375~379.
[6] 徐梦露,徐旭东.维持性血透患者高磷血症的现状与治疗进展[J].中国中西医结合肾病杂志,2016,17(6):557~559.
[7] 牛丹,吕佳,王晓培,等.司维拉姆治疗维持性透析患者高磷血症有效性和安全性观察[J].陕西医学杂志,2017,46(10):1455~1457. |
|
|
|
2019, Vol. 25 
